Cargando…
Dose Finding in Oncology: What is Impeding Coming of Age?
After a drug molecule enters clinical trials, there are primarily three levers to enhance probability of success: patient selection, dose selection and choice of combination agents. Of these, dose selection remains an under-appreciated aspect in oncology drug development despite numerous peer-review...
Autores principales: | Mayawala, Kapil, de Alwis, Dinesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314272/ https://www.ncbi.nlm.nih.gov/pubmed/35474158 http://dx.doi.org/10.1007/s11095-022-03263-5 |
Ejemplares similares
-
Correction to: Dose Finding in Oncology: What is Impeding Coming of Age?
por: Mayawala, Kapil, et al.
Publicado: (2022) -
Neocentromeres Come of Age
por: Marshall, Owen J., et al.
Publicado: (2009) -
The Silkworm Coming of Age—Early
por: Feyereisen, René, et al.
Publicado: (2012) -
Coming of Age for the Photoreceptor Synapse
por: Townes-Anderson, Ellen, et al.
Publicado: (2021) -
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response
por: Kumar, Rukmini, et al.
Publicado: (2021)